Perioral skin biopsy to study skeletal muscle protein expression

Muscle and Nerve

Volumn 41, Issue 3, 2010, Pages 392-398

  Santoro, Lucio ^a   Nolano, Maria ^b   Faraso, Stefania ^c   Fiorillo, Chiara ^d   Vitiello, Carmen ^c   Provitera, Vincenzo ^b   Aurino, Stefania ^c   Nigro, Vincenzo ^e  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b IRCCS   (Italy)

^c TELETHON INSTITUTE OF GENETICS AND MEDICINE TIGEM   (Italy)

^d Istituto di Diagnosi e Cura Hermitage Capodimonte   (Italy)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Gene therapy; Immunohistochemistry; Protein expression; Skeletal muscle; Skin biopsy

Indexed keywords

ALPHA SARCOGLYCAN; BETA DYSTROGLYCAN; CREATINE KINASE; DYSTROPHIN; GAMMA SARCOGLYCAN; MUSCLE ANTIGEN; MUSCLE PROTEIN;

ADULT; ARTICLE; BECKER MUSCULAR DYSTROPHY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DUCHENNE MUSCULAR DYSTROPHY; EXON; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GAIT DISORDER; GENE MUTATION; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LIMB GIRDLE MUSCULAR DYSTROPHY; LORDOSIS; MALE; MINIMALLY INVASIVE PROCEDURE; MISSENSE MUTATION; MIYOSHI MYOPATHY; MUSCLE BIOPSY; MUSCLE CELL; MUSCULAR DYSTROPHY; ORAL BIOPSY; ORBICULARIS ORIS MUSCLE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEFECT; PROTEIN EXPRESSION; PUNCH BIOPSY; SCOLIOSIS; SKELETAL MUSCLE; SKIN BIOPSY; TREATMENT RESPONSE; WESTERN BLOTTING;

ADULT; BIOPSY, NEEDLE; FACE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MALE; MICROSCOPY, CONFOCAL; MIDDLE AGED; MUSCLE PROTEINS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES; PATIENT SELECTION; SKIN;

EID: 77649111191     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21506     Document Type: Article

References (16)

1. Cossu G, Sampaolesi M. New therapies for Duchenne muscular dystrophy: challenger, prospects and clinical trials. Trends Mol Med 2007;12:520-526.
2. Muntoni F, Wells D. Genetic treatments in muscular dystrophies. Curr Opin Neurol 2007;20:590-594.
3. Nolano M, Provitera V, Crisci C, Stancanelli A, Wendelschafer-Crabb G, Kennedy WR, et al. Quantification of myelinated endings and mechanoreceptors in human digital skin. Ann Neurol 2003;54: 197-205.
4. Nolano M, Provitera V, Perretti A, Stancanelli A, Saltalamacchia AM, Donadio V, et al. Ross syndrome: a rare or a misknown disorder of thermoregulation? A skin innervation study on 12 subjects. Brain 2006;129:2119-2131.
5. Nigro V, Piluso G, Belsito A, Politano L, Puca AA, Papparella S, et al. Identification of a novel sarcoglycan gene at 5q33 encoding a sarcolemmal 35 kDa glycoprotein. Hum Mol Genet 1996;5:1179-1186.
6. Lu Y, Tian C, Danialou G, Gilbert R, Petrof BJ, Karpati G, et al. Targeting artificial transcription factors to the utrophin A promoter: effects on dystrophic pathology and muscle function. J Biol Chem 2008;283:34720-34727.
7. Alter J, Lou F, Rabinowitz A, Yin H, Rosenfeld J, Wilton SD, et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 2006;12:175-177.
8. van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007;357:2677-2686.
9. Aurino S, Nigro V. Readthrough stategies for stop codons in Duchenne muscular dystrophy. Acta Myol 2006;25:5-12.
10. Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007;447:87-91.
11. Bönnemann C, Finkel R, Wong B, Flanigan K, Sampson J, Sweeney L, et al. Phase 2 study of PTC124 for nonsense mutation suppression therapy of Duchenne muscular dystrophy (DMD) [abstract]. Neuromuscul Disord 2007;17:783.
12. Hirawat S, Welch EM, Elfring GL, Northcutt VJ, Paushkin S, Hwang S, et al. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration, to healthy male and female adult volunteers. J Clin Pharmacol 2007;47:430-444.
13. Haddad H, Caizergues D, Rigolet A, Masurier C, Douar AM, Gjata B, et al. Phase I-IIa gene therapy protocol for LGMD2C. Clinical strategy and implications [abstract]. Mol Ther 2007;15(suppl):S412.
14. Cooper ST, Lo HP, North KN. Single section Western blot. Neurology 2003;61:93-97.
15. Marbini A, Marcello N, Bellanova MF, Guidetti D, Ferrari A, Gemignani F. Dystrophin expression in skin biopsy. Immunohistochemical localisation of striated muscle type dystrophin. J Neurol Sci 1995; 129:29-33.
16. Takahito N, Itsuro H, Shunichi S, Tsuyoshi M, Hidetoshi F, Mitsuhiro O. Diagnosis of dystrophinopathy by skin biopsy. Muscle Nerve 2002;25:398-401.